恩杂鲁胺联合二甲双胍对比恩杂鲁胺单药治疗转移性去势抵抗性前列腺癌:随机2期试验(SAKK 08/14)
这项随机2期试验纳入mCRPC患者,比较恩杂鲁胺联合二甲双胍与恩杂鲁胺单药的疗效。主要终点15个月疾病控制率两组无差异(52% vs 56%,p=0.64),联合治疗未改善次要终点。事后分析提示PTEN表达肿瘤患者联合二甲双胍可能改善PSA进展时间(p=0.0074),超重/肥胖患者多项终点更优。
要点
- 联合二甲双胍未提高整体mCRPC患者的15个月疾病控制率或次要终点。
- PTEN表达肿瘤患者联合二甲双胍可能改善PSA进展时间,需进一步验证。
- 基线BMI≥25 kg/m2患者疾病控制率、OS、EFS等终点更优,独立于治疗组。
核心结论
- 在整体mCRPC队列中,恩杂鲁胺联合二甲双胍未改善研究终点。
- PTEN状态作为潜在预测生物标志物及肥胖悖论需进一步研究。
研究设计与样本
- 随机2期试验,2016至2021年纳入mCRPC患者,按BMI分层。
- 联合组84例,单药组82例;主要终点为15个月疾病控制率(DCR)。
主要发现
- 联合组与单药组15个月DCR分别为52%与56%(p=0.64)。
- PTEN表达肿瘤患者(n=64)联合二甲双胍可能改善TTPSAP(p=0.0074),PTEN阴性肿瘤患者(n=65)无改善(p>0.6)。
- 基线BMI≥25 kg/m2患者DCR、OS、EFS、TTPSAP及TTRP均优于BMI<25 kg/m2患者,独立于治疗组(p<0.009)。
关键数值与推荐
- 主要终点15个月DCR:联合组52% vs 单药组56%,p=0.64。
- PTEN表达亚组TTPSAP比较p=0.0074;PTEN阴性亚组p>0.6。
- BMI≥25 kg/m2与<25 kg/m2比较,多项终点p<0.009。
临床怎么用
- 不推荐在未经选择的mCRPC患者中常规联合二甲双胍与恩杂鲁胺。
- PTEN表达状态可能作为未来分层因素,但需前瞻性验证。
- 基线BMI≥25 kg/m2与更好预后相关,但机制不明,不构成治疗推荐。
局限性
- 为2期试验,样本量有限,事后分析结果需谨慎解读。
- PTEN蛋白表达为事后分析,未作为预设分层因素。
- 肥胖悖论为观察性发现,不能推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The aim of our study is to determine whether the addition of metformin to enzalutamide can improve the outcomes of men with metastatic castration-resistant prostate cancer (mCRPC). METHODS: From 2016 to 2021, patients with mCRPC were randomized to receive enzalutamide plus metformin or enzalutamide alone, with body mass index (BMI) as a stratification factor. Primary end point was disease-control rate (DCR) at 15 mo. Secondary end points included event-free survival (EFS), time to prostate-specific antigen progression (TTPSAP) or radiologic progression (TTRP), and overall survival (OS). Post hoc analyses include tumor phosphatase and tensin homolog (PTEN)-protein expression. KEY FINDINGS AND LIMITATIONS: Enzalutamide plus metformin (n = 84) did not increase DCR or secondary end points compared with enzalutamide alone (n = 82; DCR 52% vs 56%, p = 0.64). Post hoc analysis suggests that addition of metformin to enzalutamide may improve TTPSAP (p = 0.0074) in patients with PTEN-expressing tumor (n = 64), but not in patients with PTEN-negative tumor (n = 65, p > 0.6). Patients who were overweight/obese at baseline (BMI ≥25 kg/m2) had better DCR, OS, EFS, TTPSAP, and TTRP than patients with BMI <25 kg/m2, independent of treatment arm (p < 0.009). CONCLUSIONS AND CLINICAL IMPLICATIONS: The addition of metformin to enzalutamide did not improve the study end points in the whole study cohort. PTEN status as a potential predictive biomarker and the obesity paradox warrant further investigation. PATIENT SUMMARY: This study found that adding the diabetes drug metformin to standard treatment with enzalutamide did not improve outcomes in men with advanced prostate cancer. However, men whose tumors express PTEN protein seemed to benefit from metformin. Interestingly, overweight/obese men lived longer than those of normal weight.
引用
- Gillessen S, Gobat K, Cathomas R, et al. Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14). Eur Urol Oncol. 2026. PMID: 41862335. doi:10.1016/j.euo.2026.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。